Du är här

2014-04-03

aap Implantate AG: aap Implantate AG reports Q1 trauma sales growth of 46%, fueled by LOQTEQ® growth of more than 180%

aap Implantate AG / aap Implantate AG reports Q1 trauma sales growth of 46%,
fueled by LOQTEQ®growth of more than 180% . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
aap
Implantate AG (XETRA: AAQ.DE) reports, on the basis of preliminary figures,
first quarter 2014 sales of EUR 7.1 million, slightly above the guidance of
between EUR 6.8 million to EUR 7.0 million. Based on the divestment of EMCM
as per February 28, the first quarter sales include only two months of the
EMCM sales.

On a like for like basis, the continued operations (aap
Implantate AG without EMCM B.V.) show, without project sales, a sales growth
to EUR 6.1 million, a 32% increase compared to the corresponding sales of EUR
4.6 million in the first quarter of 2013. The trauma sales for the same
period increased by 46% to EUR 2.1 million; driven especially by LOQTEQ®
sales growth of more than 180%. The sales growth without project sales of
more than 30% in the first quarter for the Biomaterials business
(Biomaterials, bone cements and cementing devices) sets a good trend for the
financial year 2014.

Bruke Seyoum Alemu, COO, comments: "First quarter sales, especially those for
trauma, represent a strong start of 2014. The growth of the LOQTEQ® portfolio
is a confirmation of the positive market feedback of our LOQTEQ® technology."

The divestment of the contract manufacturing subsidiary EMCM underlines the
initiated strategic orientation to become a focused Trauma company.aap
reports it has received the 2ndinstalment of EUR 6 million for the sales of
its shares in EMCM; a total of EUR 12 million has been received so far. The
last payment of EUR 6 million is scheduled to be paid before April 30th.

Next to the dynamic Trauma business, in combination with the issued silver
coating patent in the USA in February and the development in the magnesium
technology, the company shows progress in building a broad based platform
that can address the fundamental challenges in trauma healthcare, enabling
new standards for infection prevention and resorbable implants.

Publication of the interim report for the first quarter of 2014 is scheduled
for May 15, 2014.

_______________________________________________________________________________
aap
Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All
German stock markets -

Aboutaap
Implantate AG
aap
is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that
are used in orthopedic procedures. The Company's products, which include a
full line of plating systems, cannulated screws and bone cement products, are
primarily used in the orthopedic specialty areas of trauma and spine repair.
The Company's products are sold through its direct sales force, distribution
partners and license agreements with OEM partners.aap
's stock is listed in the Prime Standard segment of the Frankfurt Stock
Exchange. For more information, please visit www.aap.de, or download the
Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or
developments.

For inquiries please contact:aap
Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap
.de

aap_PM_Q1 2014
http://hugin.info/130121/R/1774316/604835.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire

HUG#1774316

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.